Discontinued — last reported Q4 '25
West Pharmaceutical Services Payments For Excise Tax remained flat by 0.0% to $1.05M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 47.5%, from $2.00M to $1.05M. This is a positive signal — lower values indicate better performance for this metric.
An increase may indicate higher tax liabilities related to specific corporate financial maneuvers or regulatory changes.
This represents cash outflows specifically designated for excise taxes related to financing or corporate activities. It...
Highly specific to the regulatory environment and tax structure of the company's operating jurisdictions.
financing_payments_for_excise_tax| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2.00M | $1.05M | $1.05M | $1.05M | $1.05M |
| QoQ Change | — | — | — | — | — | — | — | — | — | — | -47.5% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | — | — | -47.5% |